metabolic

Retatrutide

Triple-receptor GLP-1 / GIP / glucagon.

What it is

Next-generation incretin agonist. Hits three metabolic receptors for the most aggressive fat-loss profile available.

Who it's for

Experienced, plateaued on tirzepatide, monitoring closely.

Protocol

0.5mg subq weekly, slow titration. Bloodwork required.

What to expect

Notable shifts within 4–6 weeks for most.

For research use only. Not a medical device. Fulfilled by Peptides ATX. Read the full disclaimer at checkout.